Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.700
-0.220 (-7.53%)
At close: Apr 28, 2026, 4:00 PM EDT
2.720
+0.020 (0.74%)
After-hours: Apr 28, 2026, 7:00 PM EDT
BDTX Employees
Black Diamond Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 3 or -12.50% compared to the previous year.
Employees
21
Change (1Y)
-3
Growth (1Y)
-12.50%
Revenue / Employee
$3,333,333
Profits / Employee
$1,065,095
Market Cap
154.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| ProQR Therapeutics | 187 |
| Tonix Pharmaceuticals Holding | 142 |
| Cartesian Therapeutics | 75 |
| Precision BioSciences | 68 |
| Corbus Pharmaceuticals Holdings | 36 |
| Spero Therapeutics | 25 |
| Unicycive Therapeutics | 22 |
BDTX News
- 7 days ago - Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts
- 5 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 5 months ago - Black Diamond Therapeutics Transcript: Study Update - Transcripts
- 5 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire